Hypoxia and hypoxia-inducible factor in renal disease - PubMed (original) (raw)
Review
doi: 10.1159/000148256. Epub 2008 Jul 30.
Affiliations
- PMID: 18667839
- DOI: 10.1159/000148256
Free article
Review
Hypoxia and hypoxia-inducible factor in renal disease
Masaomi Nangaku et al. Nephron Exp Nephrol. 2008.
Free article
Abstract
Tissue hypoxia occurs when local metabolism is disturbed by an imbalance between oxygen supply and consumption. In patients with chronic kidney disease, chronic hypoxia in the kidneys is the end result of multiple processes and mechanisms. Once established, however, accumulating evidence points to this chronic hypoxia as the central player and final common pathway to end-stage renal disease. The cellular response to hypoxia is centered on hypoxia-inducible factor, HIF. This factor is composed of two subunits, an oxygen-sensitive HIF-alpha subunit and a constitutively expressed HIF-beta subunit. Intracellular accumulation of HIF induces the coordinated expression of a number of adaptive genes against hypoxic insult.Three isoforms of HIF-alpha subunits have been identified, HIF-1alpha, HIF-2alpha, and HIF-3alpha, of which HIF-2alpha is involved in the regulation of erythropoietin as well as oxidative stress. HIF is regulated by prolyl hydroxylation and asparaginyl hydroxylation of the HIF-alpha subunit at the protein level. Because HIF is activated only to suboptimal levels in various pathogenic states, therapeutic activation holds promise as a novel and effective approach to the future care of end-stage renal disease.
Copyright (c) 2008 S. Karger AG, Basel.
Similar articles
- Perspective in chronic kidney disease: targeting hypoxia-inducible factor (HIF) as potential therapeutic approach.
Deshmukh AB, Patel JK, Prajapati AR, Shah S. Deshmukh AB, et al. Ren Fail. 2012;34(4):521-32. doi: 10.3109/0886022X.2011.653754. Epub 2012 Jan 23. Ren Fail. 2012. PMID: 22264075 Review. - Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase.
Nangaku M, Kojima I, Tanaka T, Ohse T, Kato H, Fujita T. Nangaku M, et al. Recent Pat Cardiovasc Drug Discov. 2006 Jun;1(2):129-39. doi: 10.2174/157489006777442522. Recent Pat Cardiovasc Drug Discov. 2006. PMID: 18221080 Review. - Hypoxia and the HIF system in kidney disease.
Nangaku M, Eckardt KU. Nangaku M, et al. J Mol Med (Berl). 2007 Dec;85(12):1325-30. doi: 10.1007/s00109-007-0278-y. Epub 2007 Nov 20. J Mol Med (Berl). 2007. PMID: 18026918 Review. - Hypoxia-inducible factor prolyl-hydroxylase: purification and assays of PHD2.
Hewitson KS, Schofield CJ, Ratcliffe PJ. Hewitson KS, et al. Methods Enzymol. 2007;435:25-42. doi: 10.1016/S0076-6879(07)35002-7. Methods Enzymol. 2007. PMID: 17998047
Cited by
- Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.
Shimada Y, Izumi Y, Yasuoka Y, Oshima T, Nagaba Y, Nanami M, Sands JM, Takahashi N, Kawahara K, Nonoguchi H. Shimada Y, et al. Int J Mol Sci. 2024 Aug 30;25(17):9468. doi: 10.3390/ijms25179468. Int J Mol Sci. 2024. PMID: 39273415 Free PMC article. - How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.
Wanner C, Nangaku M, Kraus BJ, Zinman B, Mattheus M, Hantel S, Schumacher M, Ohneberg K, Schmoor C, Inzucchi SE. Wanner C, et al. Nephrol Dial Transplant. 2024 Aug 30;39(9):1504-1513. doi: 10.1093/ndt/gfae032. Nephrol Dial Transplant. 2024. PMID: 38323492 Free PMC article. Clinical Trial. - The therapeutic prospect of zinc oxide nanoparticles in experimentally induced diabetic nephropathy.
Abd El-Baset SA, Mazen NF, Abdul-Maksoud RS, Kattaia AAA. Abd El-Baset SA, et al. Tissue Barriers. 2023 Jan 2;11(1):2069966. doi: 10.1080/21688370.2022.2069966. Epub 2022 May 3. Tissue Barriers. 2023. PMID: 35504734 Free PMC article. - Akt Inhibition as Preconditioning Treatment to Protect Kidney Cells against Anoxia.
Melis N, Carcy R, Rubera I, Cougnon M, Duranton C, Tauc M, Pisani DF. Melis N, et al. Int J Mol Sci. 2021 Dec 23;23(1):152. doi: 10.3390/ijms23010152. Int J Mol Sci. 2021. PMID: 35008578 Free PMC article. - Long Non-Coding RNAs in Oral Submucous Fibrosis: Their Functional Mechanisms and Recent Research Progress.
He Y, Wang W, Jiang P, Yang L, Guo Q, Xiang J, Gao Y, Wang Y, Chen R. He Y, et al. J Inflamm Res. 2021 Nov 3;14:5787-5800. doi: 10.2147/JIR.S337014. eCollection 2021. J Inflamm Res. 2021. PMID: 34764671 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases